Chemoprevention of Skin Cancer

  • Meyer A. Horn
  • Kenneth B. Gordon
Part of the Cancer Treatment and Research book series (CTAR, volume 106)


Non-melanoma skin cancer (NMSC) is the most prevalent of all malignancies diagnosed in men and women in the US and its incidence is rising rapidly. It has been estimated that between 900,000 and 1,200,000 new skin cancers arise in the Unites States each year (1). The large majority of these are NMSC’s. Melanoma, with an estimated 44,200 new cases in 1999 (2) is a less prevalent cutaneous malignancy, but is one with a significantly higher mortality rate than all other skin cancers combined. It is now the eighth most common carcinoma in the Unites States, and one of the most common cancers of young adults (3). In the past 10 years its incidence has nearly doubled, with a lifetime risk of about 1 in 90 (4).


Skin Cancer Human Papilloma Virus Basal Cell Carcinoma Actinic Keratosis Skin Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1).
    Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol 1994; 30(5 Pt 1):774–778.PubMedGoogle Scholar
  2. 2).
    Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999 [see comments]. CA Cancer J Clin 1999; 49(1):8–31, 1.PubMedGoogle Scholar
  3. 3).
    Gilchrest BA, Eller MS, Geller AC, Yaar M. The pathogenesis of melanoma induced by ultraviolet radiation [see comments]. N Engl J Med 1999; 340(17):1341–1348.PubMedGoogle Scholar
  4. 4).
    Hill L, Ferrini RL. Skin cancer prevention and screening: summary of the American College of Preventive Medicines practice policy statements [see comments]. CA Cancer J Clin 1998; 48(4):232–235; 1.PubMedGoogle Scholar
  5. 5).
    Chuang TY, Brashear R. Risk factors of non-melanoma skin cancer in United States veterans patients: a pilot study and review of literature. J Eur Acad Dermatol Venereol 1999; 12(2):126–132; 14.PubMedGoogle Scholar
  6. 6).
    Staples M, Marks R, Giles G. Trends in the incidence of non-melanocytic skin cancer (NMSC) treated in Australia 1985–1995: are primary prevention programs starting to have an effect? Int J Cancer 1998; 78(2):144–148; 26.PubMedGoogle Scholar
  7. 7).
    Madronich S, McKenzie RL, Bjorn LO, Caldwell MM. Changes in biologically active ultraviolet radiation reaching the Earth’s surface. J Photochem Photobiol B 1998; 46(1–3):5–19; 2.PubMedGoogle Scholar
  8. 8).
    Madronich S, de Gruijl FR. Stratospheric ozone depletion between 1979 and 1992: implications for biologically active ultraviolet-B radiation and non-melanoma skin cancer incidence. Photochem Photobiol 1994; 59(5):541–546; 3.PubMedGoogle Scholar
  9. 9).
    Sober AJ, Burstein JM. Precursors to skin cancer. Cancer 1995; 75(2 Suppl):645–650; 13.PubMedGoogle Scholar
  10. 10).
    Moy RL. Clinical presentation of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000; 42(1 Pt 2):8–10.PubMedGoogle Scholar
  11. 11).
    Cockerell CJ. Histopathology of incipient intraepidermal squamous cell carcinoma (“actinic keratosis”). J Am Acad Dermatol 2000; 42(1 Pt 2):11–17.PubMedGoogle Scholar
  12. 12).
    Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000; 42(1 Pt 2):4–7.PubMedGoogle Scholar
  13. 13).
    Hurwitz RM, Monger LE. Solar keratosis: an evolving squamous cell carcinoma. Benign or malignant? [letter]. Dermatol Surg 1995; 21(2):184.PubMedGoogle Scholar
  14. 14).
    Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet 1988; 1(8589):795–797.PubMedGoogle Scholar
  15. 15).
    Brash DE, Ponten J. Skin precancer. Cancer Sury 1998; 32:69–113; 2.Google Scholar
  16. 16).
    Harvey I, Frankel S, Marks R, Shalom D, Nolan-Farrell M. Non-melanoma skin cancer and solar keratoses II analytical results of the South Wales Skin Cancer Study. Br J Cancer 1996; 74(8):1308–1312.PubMedGoogle Scholar
  17. 17).
    Vitasa BC, Taylor HR, Strickland PT, Rosenthal FS, West S, Abbey H, Ng SK, Munoz B, Emmett EA. Association of nonmelanoma skin cancer and actinic keratosis with cumulative solar ultraviolet exposure in Maryland watermen. Cancer 1990; 65(12):2811–2817.PubMedGoogle Scholar
  18. 18).
    Luande J, Henschke CI, Mohammed N. The Tanzanian human albino skin. Natural history. Cancer 1985; 55(8):1823–1828.PubMedGoogle Scholar
  19. 19).
    Gilbody JS, Aitken J, Green A. What causes basal cell carcinoma to be the commonest cancer? Aust J Public Health 1994; 18(2):218–221; 1.PubMedGoogle Scholar
  20. 20).
    Gallagher RP, Bajdik CD, Fincham S, Hill GB, Keefe AR, Coldman A, McLean DI. Chemical exposures, medical history, and risk of squamous and basal cell carcinoma of the skin. Cancer Epidemiol Biomarkers Prey 1996; 5(6):419–424.Google Scholar
  21. 21).
    Franceschi S, Levi F, Randimbison L, La Vecchia C. Site distribution of different types of skin cancer: new aetiological clues. Int J Cancer 1996; 67(1):24–28.PubMedGoogle Scholar
  22. 22).
    Rosso S, Zanetti R, Pippione M, Sancho-Gamier H. Parallel risk assessment of melanoma and basal cell carcinoma: skin characteristics and sun exposure. Melanoma Res 1998; 8(6):573–583; 12.PubMedGoogle Scholar
  23. 23).
    Tucker MA, Halpern A, Holly EA, Hartge P, Elder DE, Sagebiel RW, Guerry D, Clark WH, Jr. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma [see comments]. JAMA 1997; 277(18):1439–1444.PubMedGoogle Scholar
  24. 24).
    Seykora J, Elder D. Dysplastic nevi and other risk markers for melanoma. Semin Oncol 1996; 23(6):682–687; 93.PubMedGoogle Scholar
  25. 25).
    Bataille V, Bishop JA, Sasieni P, Swerdlow AJ, Pinney E, Griffiths K, Cuzick J. Risk of cutaneous melanoma in relation to the numbers, types and sites of naevi: a case-control study. Br J Cancer 1996; 73(12):1605–1611; 100.PubMedGoogle Scholar
  26. 26).
    Elder DE, Clark WH, Jr., Elenitsas R, Guerry D, Halpern AC. The early and intermediate precursor lesions of tumor progression in the melanocytic system: common acquired nevi and atypical (dysplastic) nevi. Semin Diagn Pathol 1993; 10(1):18–35; 25.PubMedGoogle Scholar
  27. 27).
    Duray PH, Emstoff MS. Dysplastic nevus in histologic contiguity with acquired nonfamilial melanoma. Clinicopathologic experience in a 100-bed hospital. Arch Dermatol 1987; 123(1):80–84; 40.PubMedGoogle Scholar
  28. 28).
    Huang MT, Ma W, Yen P, Xie JG, Han J, Frenkel K, Grunberger D, Conney AH. Inhibitory effects of topical application of low doses of curcumin on 12–0- tetradecanoylphorbol-13-acetate-induced tumor promotion and oxidized DNA bases in mouse epidermis. Carcinogenesis 1997; 18(1):83–88; 20.PubMedGoogle Scholar
  29. 29).
    Osterlind A, Hou-Jensen K, Moller JO. Incidence of cutaneous malignant melanoma in Denmark 1978–1982. Anatomic site distribution, histologic types, and comparison with non-melanoma skin cancer. Br J Cancer 1988; 58(3):385–391; 24.PubMedGoogle Scholar
  30. 30).
    Mack TM, Floderus B. Malignant melanoma risk by nativity, place of residence at diagnosis, and age at migration. Cancer Causes Control 1991; 2(6):401–411; 1.PubMedGoogle Scholar
  31. 31).
    MacLennan R, Green AC, McLeod GR, Martin NG. Increasing incidence of cutaneous melanoma in Queensland, Australia. J Natl Cancer Inst 1992; 84(18):1427–1432; 8.PubMedGoogle Scholar
  32. 32).
    Ley RD. Ultraviolet radiation A-induced precursors of cutaneous melanoma in Monodelphis domestica. Cancer Res 1997; 57(17):3682–3684; 4.PubMedGoogle Scholar
  33. 33).
    Kollias N, Malallah YH, al Ajmi H, Bacier A, Johnson BE, Gonzalez S. Erythema and melanogenesis action spectra in heavily pigmented individuals as compared to fair-skinned Caucasians. Photodermatol Photoimmunol Photomed 1996; 12(5):183–188.PubMedGoogle Scholar
  34. 34).
    Young AR, Potten CS, Chadwick CA, Murphy GM, Hawk JL, Cohen AJ. Photoprotection and 5-MOP photochemoprotection from UVR-induced DNA damage in humans: the role of skin type. J Invest Dermatol 1991; 97(5):942–948.PubMedGoogle Scholar
  35. 35).
    Amblard P, Beani J, Gautron R, Reymond J, Doyon B. Statistical study of individual variations in sunburn sensitivity in 303 volunteers without photodermatosis. Arch Dermatol Res 1982; 274(3–4):195–206.PubMedGoogle Scholar
  36. 36).
    Young AR. The sunburn cell. Photodermatol 1987; 4(3):127–134.PubMedGoogle Scholar
  37. 37).
    Ananthaswamy HN, Ullrich SE, Mascotto RE, Fourtanier A, Loughlin SM, Khaskina P, Bucana CD, Kripke ML. Inhibition of solar simulator-induced p53 mutations and protection against skin cancer development in mice by sunscreens. J Invest Dermatol 1999; 112(5):763–768; 6.PubMedGoogle Scholar
  38. 38).
    Coldiron BM. Thinning of the ozone layer: facts and consequences [see comments]. J Am Acad Dermatol 1992; 27(5 Pt 1):653–662; 3.PubMedGoogle Scholar
  39. 39).
    Lowe NJ, Meyers DP, Wieder JM, Luftman D, Borget T, Lehman MD, Johnson AW, Scott IR. Low doses of repetitive ultraviolet A induce morphologic changes in human skin. J Invest Dermatol 1995; 105(6):739–743.PubMedGoogle Scholar
  40. 40).
    Strickland PT. Photocarcinogenesis by near-ultraviolet (UVA) radiation in Sencar mice. J Invest Dermatol 1986; 87(2):272–275.PubMedGoogle Scholar
  41. 41).
    Sterenborg HJ, van der Leun JC. Tumorigenesis by a long wavelength UV-A source. Photochem Photobiol 1990; 51(3):325–330.PubMedGoogle Scholar
  42. 42).
    Atillasoy ES, Elenitsas R, Sauter ER, Soballe PW, Herlyn M. UVB induction of epithelial tumors in human skin using a RAG-1 mouse xenograft model. J Invest Dermatol 1997; 109(6):704–709PubMedGoogle Scholar
  43. 43).
    Nomura T, Nakajima H, Hongyo T, Taniguchi E, Fukuda K, Li LY, Kurooka M, Sutoh K, Hande PM, Kawaguchi T, Ueda M, Takatera H. Induction of cancer, actinic keratosis, and specific p53 mutations by UVB light in human skin maintained in severe combined immunodeficient mice. Cancer Res 1997; 57(11):2081–2084; 24.PubMedGoogle Scholar
  44. 44).
    Soballe PW, Montone KT, Satyamoorthy K, Nesbit M, Herlyn M. Carcinogenesis in human skin grafted to SCID mice. Cancer Res 1996; 56(4):757–764PubMedGoogle Scholar
  45. 45).
    Wolf P, Donawho CK, Kripke ML. Effect of sunscreens on UV radiation-induced enhancement of melanoma growth in mice [see comments]. J Nati Cancer Inst 1994; 86(2):99–105Google Scholar
  46. 46).
    Livneh Z, Cohen-Fix 0, Skaliter R, Elizur T. Replication of damaged DNA and the molecular mechanism of ultraviolet light mutagenesis. Crit Rev Biochem Mol Biol 1993; 28(6):465–513PubMedGoogle Scholar
  47. 47).
    Grossman D, Leffell DJ. The molecular basis of nonmelanoma skin cancer: new understanding. Arch Dermatol 1997; 133(10):1263–1270PubMedGoogle Scholar
  48. 48).
    Mitchell DL, Nairn RS. The biology of the (6–4) photoproduct. Photochem Photobiol 1989; 49(6):805–819PubMedGoogle Scholar
  49. 49).
    Drobetsky EA, Turcotte J, Chateauneuf A. A role for ultraviolet A in solar mutagenesis. Proc Nati Acad Sci U S A 1995; 92(6):2350–2354Google Scholar
  50. 50).
    Cleaver JE. Defective repair replication of DNA in xeroderma pigmentosum. Nature 1968; 218(142):652–656.PubMedGoogle Scholar
  51. 51).
    Lehman AR, Kirk-Bell S, Arlett CF, Paterson MC, Lohman PH, Weerd-Kastelein EA, Bootsma D. Xeroderrna pigmentosum cells with normal levels of excision repair have a defect in DNA synthesis after UV-irradiation. Proc Nati Acad Sci U S A 1975; 72(1):219–223.Google Scholar
  52. 52).
    Kraemer KH, DiGiovanna JJ, Peck GL. Chemoprevention of skin cancer in xeroderma pigmentosum. J Dermatol 1992; 19(11):715–718; 25.PubMedGoogle Scholar
  53. 53).
    Wikonkal NM, Brash DE. Ultraviolet radiation induced signature mutations in photocarcinogenesis. J Investig Dermatol Symp Proc 1999; 4(1):6–10PubMedGoogle Scholar
  54. 54).
    Lane DP. Cancer. p53, guardian of the genome [news; comment] [see comments]. Nature 1992; 358(6381):15–16PubMedGoogle Scholar
  55. 55).
    Brash DE, Ziegler A, Jonason AS, Simon JA, Kunala S, Leffell DJ. Sunlight and sunburn in human skin cancer: p53, apoptosis, and tumor promotion. J Investig Dermatol Symp Proc 1996; 1(2):136–142.PubMedGoogle Scholar
  56. 56).
    Alcslen LA, Monstad SE, Larsen B, Straume 0, Ogreid D. Frequent mutations of the p53 gene in cutaneous melanoma of the nodular type. Int.1 Cancer 1998; 79(I):91–95.Google Scholar
  57. 57).
    Whiteman DC, Parsons PG, Green AC. p53 expression and risk factors for cutaneous melanoma: a case-control study. Int J Cancer 1998; 77(6):843–848.PubMedGoogle Scholar
  58. 58).
    Harris CC. p53: at the crossroads of molecular carcinogenesis and molecular epidemiology. J Investig Dermatol Symp Proc 1996; 1(2):115–118.PubMedGoogle Scholar
  59. 59).
    Buckman SY, Gresham A, Hale P, Hruza G, Anast J, Masferrer J, Pentland AP. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 1998; 19(5):723–729PubMedGoogle Scholar
  60. 60).
    Ziegler A, Jonason AS, Leffell DJ, Simon JA, Sharma HW, Kimmelman J, Remington L, Jacks T, Brash DE. Sunburn and p53 in the onset of skin cancer [see comments]. Nature 1994; 372(6508):773–776PubMedGoogle Scholar
  61. 6 1).
    van der Schroeff JG, Evers LM, Boot AJ, Bos JL. Ras oncogene mutations in basal cell carcinomas and squamous cell carcinomas of human skin. J Invest Dermatol 1990; 94(4):423–425PubMedGoogle Scholar
  62. 62).
    Breitkreutz D, Boukamp P, Ryle CM, Stark HJ, Roop DR, Fusenig NE. Epidermal morphogenesis and keratin expression in c-Ha-ras-transfected tumorigenic clones of the human HaCaT cell line. Cancer Res 1991; 51(16):4402–4409PubMedGoogle Scholar
  63. 63).
    Boukamp P, Stanbridge EJ, Foo DY, Cerutti PA, Fusenig NE. c-Ha-ras oncogene expression in immortalized human keratinocytes (HaCaT) alters growth potential in vivo but lacks correlation with malignancy. Cancer Res 1990; 50(9):2840–2847PubMedGoogle Scholar
  64. 64).
    Aszterbaum M, Beech J, Epstein EH, Jr. Ultraviolet radiation mutagenesis of hedgehog pathway genes in basal cell carcinomas. J Investig Dermatol Symp Proc 1999; 4(1):41–45PubMedGoogle Scholar
  65. 65).
    Shafei-Benaissa E, Savage JR, Babin P, Larregue M, Papworth D, Tanzer J, Bonnetblanc JM, Huret JL. The naevoid basal-cell carcinoma syndrome (Gorlin syndrome) is a chromosomal instability syndrome. Mutat Res 1998; 397(2):287–292PubMedGoogle Scholar
  66. 66).
    Gailani MR, Leffell DJ, Ziegler A, Gross EG, Brash DE, Bale AE. Relationship between sunlight exposure and a key genetic alteration in basal cell carcinoma [see comments]. J Natl Cancer Inst 1996; 88(6):349–354.PubMedGoogle Scholar
  67. 67).
    Wei Q, Matanoski GM, Farmer ER, Hedayati MA, Grossman L. DNA repair and aging in basal cell carcinoma: a molecular epidemiology study [published erratum appears in Proc Natl Acad Sci U S A 1993 Jun 1;90(11):5378]. Proc Natl Acad Sci U S A 1993; 90(4):1614–1618.PubMedGoogle Scholar
  68. 68).
    Pierceall WE, Goldberg LH, Ananthaswamy FIN. Presence of human papilloma virus type 16 DNA sequences in human nonmelanoma skin cancers. J Invest Dermatol 1991; 97(5):880–884PubMedGoogle Scholar
  69. 69).
    Purdie KJ, Pennington J, Proby CM, Khalaf S, de Villiers EM, Leigh IM, Storey A. The promoter of a novel human papillomavirus (HPV77) associated with skin cancer displays UV responsiveness, which is mediated through a consensus p53 binding sequence. EMBO J 1999; 18(19):5359–5369PubMedGoogle Scholar
  70. 70).
    Kripke ML. Immunological unresponsiveness induced by ultraviolet radiation. Immunol Rev 1984; 80:87–102PubMedGoogle Scholar
  71. 71).
    Simon JC, Tigelaar RE, Bergstresser PR, Edelbaum D, Cruz PD, Jr. Ultraviolet B radiation converts Langerhans cells from immunogenic to tolerogenic antigen-presenting cells. Induction of specific clonal anergy in CD4+ T helper 1 cells. J Immunol 1991; 146(2):485–491PubMedGoogle Scholar
  72. 72).
    Spellman CW, Tomasi TB. Ultraviolet light-induced suppression of antigen presentation. J Clin Immunol 1983; 3(2):105–110PubMedGoogle Scholar
  73. 73).
    Blauvelt A, Asada H, Klaus-Kovtun V, Altman DJ, Lucey DR, Katz SI. Interleukin15 mRNA is expressed by human keratinocytes Langerhans cells, and blood-derived dendritic cells and is downregulated by ultraviolet B radiation. J Invest Dermatol 1996; 106(5):1047–1052PubMedGoogle Scholar
  74. 74).
    Wolf P, Yarosh DB, Kripke ML. Effects of sunscreens and a DNA excision repair enzyme on ultraviolet radiation-induced inflammation, immune suppression, and cyclobutane pyrimidine dimer formation in mice. J Invest Dermatol 1993; 101(4):523–527Google Scholar
  75. 75).
    Kripke ML. Antigenicity of murine skin tumors induced by ultraviolet light. J Natl Cancer Inst 1974; 53(5) 1333–1336.PubMedGoogle Scholar
  76. 76).
    Wang CY, Brodland DG, Su WP. Skin cancers associated with acquired immunodeficiency syndrome. Mayo Clin Proc 1995; 70(8):766–772PubMedGoogle Scholar
  77. 77).
    Hartevelt MM, Bavinck JN, Kootte AM, Vermeer BJ, Vandenbroucke JP. Incidence of skin cancer after renal transplantation in The Netherlands. Transplantation 1990; 49 (3) :506–509PubMedGoogle Scholar
  78. 78).
    Euvrard S, Kanitakis J, Pouteil-Noble C, Dureau G, Touraine JL, Faure M, Claudy A, Thivolet J. Comparative epidemiologic study of premalignant and malignant epithelial cutaneous lesions developing after kidney and heart transplantation. J Am Acad Dermatol 1995; 33(2 Pt 1):222–229PubMedGoogle Scholar
  79. 79).
    Webb MC, Compton F, Andrews PA, Koffman CG. Skin tumours posttransplantation: a retrospective analysis of 28 years’ experience at a single centre. Transplant Proc 1997; 29 (1–2):828–830Google Scholar
  80. 80).
    Dyall-Smith D, Trowell H, Dyall-Smith ML. Benign human papillomavirus infection in renal transplant recipients. Int J Dermatol 1991; 30(11):785–789PubMedGoogle Scholar
  81. 81).
    Barr BB, Benton EC, McLaren K, Bunney MH, Smith IW, Blessing K, Hunter JA. Human papilloma virus infection and skin cancer in renal allograft recipients. Lancet 1989; 1(8630):124–129PubMedGoogle Scholar
  82. 82).
    Harwood CA, Spink PJ, Surentheran T, Leigh IM, Hawke JL, Proby CM, Breuer J, McGregor JM. Detection of human papillomavirus DNA in PUVA-associated non-melanoma skin cancers. J Invest Dermatol 1998; 111(1):123–127PubMedGoogle Scholar
  83. 83).
    Nataraj AJ, Black HS, Ananthaswamy HN. Signature p53 mutation at DNA cross-linking sites in 8-methoxypsoralen and ultraviolet A (PUVA)-induced murine skin cancers. Proc Nati Acad Sci U S A 1996; 93(15):7961–7965Google Scholar
  84. 84).
    Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study [see comments]. N Engl J Med 1997; 336(15):1041–1045.PubMedGoogle Scholar
  85. 85).
    Rosen CF. Photoprotection. Semin Cutan Med Surg 1999; 18(4):307–314.PubMedGoogle Scholar
  86. 86).
    Wolf P, Cox P, Yarosh DB, Kripke ML. Sunscreens and T4N5 liposomes differ in their ability to protect against ultraviolet-induced sunburn cell formation, alterations of dendritic epidermal cells, and local suppression of contact hypersensitivity. J Invest Dermatol 1995; 104(2):287–292PubMedGoogle Scholar
  87. 87).
    Ananthaswamy HN, Loughlin SM, Cox P, Evans RL, Ullrich SE, Kripke ML. Sunlight and skin cancer: inhibition of p53 mutations in UV-irradiated mouse skin by sunscreens. Nat Med 1997; 3(5):510–514PubMedGoogle Scholar
  88. 88).
    Ananthaswamy HN, Fourtanier A, Evans RL, Tison S, Medaisko C, Ullrich SE, Kripke ML. p53 Mutations in hairless SKH-hrl mouse skin tumors induced by a solar simulator. Photochem Photobiol 1998; 67(2):227–232.PubMedGoogle Scholar
  89. 89).
    Kligman LH. Photoaging. Manifestations, prevention, and treatment. Dermatol Clin 1986; 4(3):517–528.PubMedGoogle Scholar
  90. 90).
    Flindt-Hansen H, Thune P, Eeg-Larsen T. The effect of short-term application of PABA on photocarcinogenesis. Acta Derm Venereol 1990; 70(1):72–75.PubMedGoogle Scholar
  91. 91).
    Ullrich SE, Kim TH, Ananthaswamy Kripke ML. Sunscreen effects on UV- induced immune suppression. J Investig Dermatol Symp Proc 1999; 4(1):65–69PubMedGoogle Scholar
  92. 92).
    Thompson SC, Jolley D, Marks R. Reduction of solar keratoses by regular sunscreen use [see comments]. N Engl J Med 1993; 329(16):1147–1151PubMedGoogle Scholar
  93. 93).
    Naylor MF, Boyd A, Smith DW, Cameron GS, Hubbard D, Neldner KH. High sun protection factor sunscreens in the suppression of actinic neoplasia. Arch Dermatol 1995; 131(2):170–175PubMedGoogle Scholar
  94. 94).
    Green A, Williams G, Neale R, Hart V, Leslie D, Parsons P, Marks GC, Gaffney P, Battistutta D, Frost C, Lang C, Russell A. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial [published erratum appears in Lancet 1999 Sep 18;354(9183):1038] [see comments]. Lancet 1999; 354(9180):723–729Google Scholar
  95. 95).
    Setlow RB, Grist E, Thompson K, Woodhead AD. Wavelengths effective in induction of malignant melanoma. Proc Natl Acad Sci U S A 1993; 90(14):6666–6670.PubMedGoogle Scholar
  96. 96).
    Ley RD, Applegate LA, Padilla RS, Stuart TD. Ultraviolet radiation--induced malignant melanoma in Monodelphis domestica. Photochem Photobiol 1989; 50(1):1–5Google Scholar
  97. 97).
    Autier P, Dore JF, Schifflers E, Cesarini JP, Bollaerts A, Koelmel KF, Gefeller 0, Liabeuf A, Lejeune F, Lienard D. Melanoma and use of sunscreens: an Eortc case-control study in Germany, Belgium and France. The EORTC Melanoma Cooperative Group. Int J Cancer 1995; 61(6):749–755PubMedGoogle Scholar
  98. 98).
    Autier P, Dor JF, grier N, Li nD, Panizzon R, Lejeune FJ, Guggisberg D, Eggermont AM. Sunscreen use and duration of sun exposure: a double-blind, randomized trial [see comments]. J Natl Cancer Inst 1999; 91(15):1304–1309PubMedGoogle Scholar
  99. 99).
    Dinehart SM. The treatment of actinic keratoses. J Am Acad Dermatol 2000; 42(1 Pt 2):25–28.PubMedGoogle Scholar
  100. 100).
    Coleman WP, III, Yarborough JM, Mandy SH. Dermabrasion for prophylaxis and treatment of actinic keratoses. Dermatol Surg 1996; 22(1):17–21.PubMedGoogle Scholar
  101. 101).
    Eaglstein WH, Weinstein GD, Frost P. Fluorouracil: mechanism of action in human skin and actinic keratoses. I. Effect on DNA synthesis in vivo. Arch Dermatol 1970; 101(2):132–139.PubMedGoogle Scholar
  102. 102).
    Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B 1990; 6(1–2):143–148.PubMedGoogle Scholar
  103. 103).
    Kurwa HA, Yong-Gee SA, Seed PT, Markey AC, Barlow RJ. A randomized paired comparison of photodynamic therapy and topical 5- fluorouracil in the treatment of actinic keratoses. J Am Acad Dermatol 1999; 41(3 Pt 1):414–418.PubMedGoogle Scholar
  104. 104).
    Jeffes EW, McCullough JL, Weinstein GD, Fergin PE, Nelson JS, Shull TF, Simpson KR, Bukaty LM, Hoffman WL, Fong NL. Photodynamic therapy of actinic keratosis with topical 5-aminolevulinic acid. A pilot dose-ranging study. Arch Dermatol 1997; 133(6):727–732.PubMedGoogle Scholar
  105. 105).
    Cairnduff F, Stringer MR, Hudson EL Ash DV, Brown SB. Superficial photodynamic therapy with topical 5-aminolaevulinic acid for superficial primary and secondary skin cancer. Br J Cancer 1994; 69(3):605–608; 16.Google Scholar
  106. 106).
    DiGiovanna JJ. Retinoid chemoprevention in the high-risk patient. J Am Acad Dermatol 1998; 39(2 Pt 3):82–85; 1.Google Scholar
  107. 107).
    Kwa RE, Campana K, Moy RL. Biology of cutaneous squamous cell carcinoma [see comments]. J Am Acad Dermatol 1992; 26(1):1–26.PubMedGoogle Scholar
  108. 108).
    Axelrod M, Serafin D, Klitzman B. Ultraviolet light and free radicals: an immunologic theory of epidermal carcinogenesis. Plast Reconstr Surg 1990; 86(3):582–593.PubMedGoogle Scholar
  109. 109).
    Malkovsky M, Dore C, Hunt R, Palmer L, Chandler P, Medawar PB. Enhancement of specific antitumor immunity in mice fed a diet enriched in vitamin A acetate. Proc Natl Acad Sci U S A 1983; 80(20):6322–6326.Google Scholar
  110. 110).
    Diaz BV, Lenoir MC, Ladoux A, Frelin C, Demarchez M, Michel S. Regulation of vascular endothelial growth factor expression in human keratinocytes by retinoids. J Biol Chem 2000; 275(1):642–650PubMedGoogle Scholar
  111. 111).
    Lingen MW, Polverini PJ, Bouck NP. Retinoic acid and interferon alpha act synergistically as antiangiogenic and antitumor agents against human head and neck squamous cell carcinoma. Cancer Res 1998; 58(23):5551–5558PubMedGoogle Scholar
  112. 112).
    Hsu MC. Systemic treatment of neoplastic conditions with retinoids. J Am Acad Dermatol 1998; 39(2 Pt 3):108–113Google Scholar
  113. 113).
    Peck GL. Topical tretinoin in actinic keratosis and basal cell carcinoma. J Am Acad Dermatol 1986; 15(4 Pt 2):829–835PubMedGoogle Scholar
  114. 114).
    Kraemer KH, DiGiovanna JJ, Moshell AN, Tarone RE, Peck GL. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 1988; 318(25):1633–1637PubMedGoogle Scholar
  115. 115).
    McKenna DB, Murphy GM. Skin cancer chemoprophylaxis in renal transplant recipients: 5 years of experience using low-dose acitretin [In Process Citation]. Br J Dermatol 1999; 140(4):656–660PubMedGoogle Scholar
  116. 116).
    Rook AH, Jaworsky C, Nguyen T, Grossman RA, Wolfe JT, Witmer WK, Kligman AM. Beneficial effect of low-dose systemic retinoid in combination with topical tretinoin for the treatment and prophylaxis of premalignant and malignant skin lesions in renal transplant recipients. Transplantation 1995; 59(5):714–719PubMedGoogle Scholar
  117. 117).
    Moon TE, Levine N, Cartmel B, Bangert J, Rodney S, Schreiber M, Peng YM, Ritenbaugh C, Meyskens F, Alberts D. Design and recruitment for retinoid skin cancer prevention (SKICAP) trials. The Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol Biomarkers Prey 1995; 4(6):661–669Google Scholar
  118. 118).
    Tangrea JA, Edwards BK, Taylor PR, Hartman AM, Peck GL, Salasche SJ, Menon PA, Benson PM, Mellette JR, Guill MA. Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: a multicenter clinical trial. Isotretinoin-Basal Cell Carcinoma Study Group [see comments]. J Natl Cancer Inst 1992; 84(5):328–332.PubMedGoogle Scholar
  119. 119).
    Vuillaume M, Calvayrac R, Best-Belpomme M, Tarroux P, Hubert M, Decroix Y, Sarasin A. Deficiency in the catalase activity of xeroderma pigmentosum cell and simian virus 40-transformed human cell extracts. Cancer Res 1986; 46(2):538–544.PubMedGoogle Scholar
  120. 120).
    Schallreuter KU, Pittelkow MR, Wood JM. Defects in antioxidant defense and calcium transport in the epidermis of xeroderma pigmentosum patients. Arch Dermatol Res 1991; 283(7):449–455.PubMedGoogle Scholar
  121. 121).
    Vuillaume M, Decroix Y, Calvayrac R, Vallot R, Best-Belpomme M. [Xeroderma pigmentosum: development of photoformation of hydrogen peroxide and catalytic activity in skin cells; application to an early diagnosis and to a tentative treatment]. C R Seances Acad Sci III 1983; 296(18):845–850.PubMedGoogle Scholar
  122. 122).
    Schallreuter KU. Pseudocatalase treatment in xeroderma pigmentosum: a case report [In Process Citation]. Br J Dermatol 1999; 140(6):1190–1191.PubMedGoogle Scholar
  123. 123).
    Chen W, Barthelman M, Martinez J, Alberts D, Gensler HL. Inhibition of cyclobutane pyrimidine dimer formation in epidermal p53 gene of UV-irradiated mice by alpha-tocopherol. Nutr Cancer 1997; 29(3):205–211.PubMedGoogle Scholar
  124. 124).
    Greenberg ER, Baron JA, Stukel TA, Stevens MM, Mandel JS, Spencer SK, Elias PM, Lowe N, Nierenberg DW, Bayrd G. A clinical trial of beta carotene to prevent basal-cell and squamous-cell cancers of the skin. The Skin Cancer Prevention Study Group [published erratum appears in N Engl J Med 1991 Oct 31;325(18):1324] [see comments]. N Engl J Med 1990; 323(12):789–795; 7.PubMedGoogle Scholar
  125. 125).
    Karagas MR, Greenberg ER, Nierenberg D, Stukel TA, Morris JS, Stevens MM, Baron JA. Risk of squamous cell carcinoma of the skin in relation to plasma selenium, alpha-tocopherol, beta-carotene, and retinol: a nested case-control study. Cancer Epidemiol Biomarkers Prey 1997; 6(1):25–29Google Scholar
  126. 126).
    Nakamura T, Pinnell SR, Darr D, Kurimoto I, Itami S, Yoshikawa K, Streilein JW. Vitamin C abrogates the deleterious effects of UVB radiation on cutaneous immunity by a mechanism that does not depend on TNF-alpha. J Invest Dermatol 1997; 109(1):20–24.PubMedGoogle Scholar
  127. 127).
    Burke KE, Combs GF, Jr., Gross EG, Bhuyan KC, Abu-Libdeh H. The effects of topical and oral L-selenomethionine on pigmentation and skin cancer induced by ultraviolet irradiation. Nutr Cancer 1992; 17(2):123–137PubMedGoogle Scholar
  128. 128).
    Overvad K, Thorling EB, Bjerring P, Ebbesen P. Selenium inhibits UV-light-induced skin carcinogenesis in hairless mice. Cancer Lett 1985; 27(2):163–170PubMedGoogle Scholar
  129. 129).
    Clark LC, Combs GF, Jr., Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, Krongrad A, Lesher JL, Jr., Park HK, Sanders BB, Jr., Smith CL, Taylor JR. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group [see comments] [published erratum appears in JAMA 1997 May 21;277(19):1520]. JAMA 1996; 276(24):1957–1963; 6.Google Scholar
  130. 130).
    Katiyar SK, Korman NJ, Mukhtar H, Agarwal R. Protective effects of silymarin against photocarcinogenesis in a mouse skin model. J Natl Cancer Inst 1997; 89(8):556–566PubMedGoogle Scholar
  131. 131).
    Huang MT, Lysz T, Ferraro T, Abidi TF, Laskin JD, Conney AH. Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis. Cancer Res 1991; 51(3):813–819PubMedGoogle Scholar
  132. 132).
    Srivastava R. Inhibition of neutrophil response by curcumin. Agents Actions 1989; 28(3–4):298–303PubMedGoogle Scholar
  133. 133).
    Jee SH, Shen SC, Tseng CR, Chiu HC, Kuo ML. Curcumin induces a p53-dependent apoptosis in human basal cell carcinoma cells. J Invest Dermatol 1998; 111(4):656–661PubMedGoogle Scholar
  134. 134).
    Azuine MA, Bhide SV. Chemopreventive effect of turmeric against stomach and skin tumors induced by chemical carcinogens in Swiss mice. Nutr Cancer 1992; 17(1):77–83Google Scholar
  135. 135).
    Limtrakul P, Lipigorngoson S, Namwong O, Apisariyakul A, Dunn FW. Inhibitory effect of dietary curcumin on skin carcinogenesis in mice. Cancer Lett 1997; 116(2):197–203; 17.Google Scholar
  136. 136).
    Lee E, Park KK, Lee JM, Chun KS, Kang JY, Lee SS, Surh YJ. Suppression of mouse skin tumor promotion and induction of apoptosis in HL-60 cells by Alpinia oxyphylla Miguel (Zingiberaceae). Carcinogenesis 1998; 19(8):1377–1381; 11.PubMedGoogle Scholar
  137. 137).
    Park KK, Chun KS, Lee JM, Lee SS, Surh YJ. Inhibitory effects of [6]-gingerol, a major pungent principle of ginger, on phorbol ester-induced inflammation, epidermal ornithine decarboxylase activity and skin tumor promotion in ICR mice [published erratum appears in Cancer Lett 1998 Sep 25;131(2):231]. Cancer Lett 1998; 129(2):139–144; 12.Google Scholar
  138. 138).
    Record IR, Dreosti IE. Protection by black tea and green tea against UVB and UVA + B induced skin cancer in hairless mice. Mutat Res 1998; 422(1):191–199PubMedGoogle Scholar
  139. 139).
    Liu Q, Wang Y, Crist KA, Wang ZY, Lou YR, Huang MT, Conney AH, You M. Effect of green tea on p53 mutation distribution in ultraviolet B radiation-induced mouse skin tumors. Carcinogenesis 1998; 19(7):1257–1262.PubMedGoogle Scholar
  140. 140).
    Lu YP, Lou YR, Xie JG, Yen P, Huang MT, Conney AH. Inhibitory effect of black tea on the growth of established skin tumors in mice: effects on tumor size, apoptosis, mitosis and bromodeoxyuridine incorporation into DNA. Carcinogenesis 1997; 18(11):2163–2169.PubMedGoogle Scholar
  141. 141).
    Zhao JF, Zhang YJ, Jin XH, Athar M, Santella RM, Bickers DR, Wang ZY. Green tea protects against psoralen plus ultraviolet A-induced photochemical damage to skin. J Invest Dermatol 1999; 113(6):1070–1075.PubMedGoogle Scholar
  142. 142).
    Black HS. Influence of dietary factors on actinically-induced skin cancer. Mutat Res 1998; 422(1):185–190PubMedGoogle Scholar
  143. 143).
    Black HS, Herd JA, Goldberg LH, Wolf JE, Jr., Thornby JI, Rosen T, Bruce S, Tschen JA, Foreyt JP, Scott LW. Effect of a low-fat diet on the incidence of actinic keratosis. N Engl J Med 1994; 330(18):1272–1275PubMedGoogle Scholar
  144. 144).
    Black HS, Thornby JI, Wolf JE, Jr., Goldberg LH, Herd JA, Rosen T, Bruce S, Tschen JA, Scott LW, Jaax S. Evidence that a low-fat diet reduces the occurrence of non-melanoma skin cancer. Int J Cancer 1995; 62(2):165–169PubMedGoogle Scholar
  145. 145).
    van Dam RM, Huang Z, Giovannucci E, Rimm EB, Hunter DJ, Colditz GA, Stampfer MJ, Willett WC. Diet and basal cell carcinoma of the skin in a prospective cohort of men. Am J Clin Nutr 2000; 71(1):135–141PubMedGoogle Scholar
  146. 146).
    Fischer SM, Lo HH, Gordon GB, Seibert K, Kelloff G, Lubet RA, Conti CJ. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog 1999; 25(4):231–240PubMedGoogle Scholar
  147. 147).
    Reeve VE, Matheson MJ, Bosnic M, Boehm-Wilcox C. The protective effect of indomethacin on photocarcinogenesis in hairless mice. Cancer Lett 1995; 95(1–2):213–219.PubMedGoogle Scholar
  148. 148).
    Gordon KB; Roenigk HH; Gendleman M. Treatment of multiple lesions of Bowen disease with isotretinoin and interferon alfa. Efficacy of combination chemotherapy. Arch Dermatol 1997;133(6):691–3PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Meyer A. Horn
  • Kenneth B. Gordon

There are no affiliations available

Personalised recommendations